MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Drug: MSB0011359C
- Registration Number
- NCT02517398
- Brief Summary
The main purpose of this Phase I study was to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means the study drug has not previously been given to humans or has only been given to a limited number of people, although it has been extensively studied in animals. Based on this information, it is hoped to find out which dose could be best for the treatment of patients. There are two parts of this research study: a dose-escalation part and an expansion part. Dose escalation means that the first people taking part in the study will receive low doses of the study drug, and as more people take part, the additional participants will receive a higher dose. This is done to find the safest dose for the study drug. Expansion means that after the dose-escalation part of the study has looked at the safety and effectiveness of different doses, many more people will be invited to take part in the study and will receive the study drug at the safest dose. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.
- Detailed Description
This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial wascomposed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of dose limiting toxicities (DLTs), followed by a consecutive parallel-group expansion in selected solid tumor in dications. Cohorts of 3 subjects with metastatic or locally advanced solid tumors, for which no standard effective therapy exists or standard therapy has failed, will receive MSB0011359C (M7824) at escalating dose levels. After determination of the Maximum tolerated dose (MTD), enrollment in several expansion cohorts will be opened to determine the safety, pharmacokinetic (PK) / Pharmacodynamic, and clinical activity of MSB0011359C (M7824). Subjects who have experienced a confirmed complete response (CR) should continue treatment through the end of 12 months, although additional treatment is possible. In the case of progressive disease (PD), subjects should continue treatment through their next tumor assessment. Additional indications will be planned based on emerging data in the field.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 600
- Ability to understand the purpose of the study, provide signed and dated informed consent, and able to comply with all procedures
- In Japan, if a subject is < 20 years, the written informed consent from his/her parent or guardian will be required in addition to the subject's written consent
- Male or female subjects aged greater than or equal to (>=) 18 years
- Life expectancy >= 12 weeks as judged by the Investigator
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at trial entry
- Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Adequate hematological, hepatic and renal function as defined in the protocol
- Effective contraception for both male and female subjects if the risk of conception exists
Other protocol-defined inclusion criteria could apply.
- Concurrent treatment with non-permitted drugs and other interventions
- Anticancer treatment within 28 days before the start of trial treatment, for example cyto reductive therapy, radiotherapy (with the exception of palliative radiotherapy delivered in a normal organ-spearing technique), immune therapy, or cytokine therapy
- Major surgery within 28 days before the start of trial treatment (prior diagnostic biopsy is permitted)
- Systemic therapy with immunosuppressive agents within 7 days before the start of trial treatment; or use of any investigational drug within 28 days before the start of trial treatment
- Previous malignant disease (other than the target malignancy to be investigated in this trial) within the last 3 years. Subjects with history of cervical carcinoma in situ, superficial or non invasive bladder cancer or basal cell or squamous cell cancer in situ previously treated with curative intent are NOT excluded. Subjects with other localized malignancies treated with curative intent need to be discussed with the Medical Monitor.
- Rapidly progressive disease which, in the opinion of the Investigator, may predispose to inability to tolerate treatment or trial procedures
- Subjects with active central nervous system (CNS) metastases causing clinical symptoms or metastases that require therapeutic intervention are excluded
- Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (eg, corneal transplant, hair transplant)
Other protocol-defined exclusion criteria could apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description MSB0011359C (M7824) MSB0011359C -
- Primary Outcome Measures
Name Time Method Dose-escalation: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs From start of study drug administration up to 139 weeks Adverse event (AE): any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAE: AE with onset after start of treatment or with onset date before the treatment start date but worsening after the treatment start date. TEAEs included both serious and non-serious TEAEs.
Dose-escalation: Number of Participants With Treatment-Related TEAEs, Treatment-Related Serious TEAEs and Treatment-related TEAEs Leading to Death From start of study drug administration up to 139 weeks Treatment-related TEAEs are any untoward medical occurrence in a participant who received study drug with causal relationship with the investigational product as assessed by the investigator. Related TEAEs were events with relationship missing, unknown or yes. Number of participants With treatment-related TEAEs, treatment-related serious TEAEs and treatment-related TEAE leading to death were reported.
Number of Participants With TEAEs and Related TEAEs Based on Severity According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.03 From start of study drug administration up to 139 weeks AEs were graded according to severity using NCI-CTCAE Version 4.03. Severity of TEAEs were graded as Grade 1: mild (not causing any significant problem, dose adjustment not required), Grade 2: moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event), Grade 3: Severe (caused problem that interferes significantly with usual activities or the clinical status, study drug stopped due to adverse event), Grade 4: Life-threatening, Grade 5: Death. Number of Participants with TEAEs and Related TEAEs Based on Severity having Grade greater than or equal to (\>=) 3 and Grade \>=4 were reported.
Dose-escalation: Number of Participants With Dose-Limiting Toxicities According to the National Cancer Institute Common Terminology Criteria For Adverse Events(NCI-CTCAE), v4.03 From start of study drug administration up to 21 days A DLT was defined as any grade \>= 3 Adverse Event (AE) suspected to be related to IMP by the Investigator and / or Sponsor occurring in the DLT evaluation period confirmed by the Safety Monitoring Committee (SMC) to be relevant for the IMP treatment. According to the NCI-CTCAE, v4.03, occurring in the DLT evaluation period and assessed to be related to study treatment by the Investigator and / or Sponsor confirmed by the safety monitoring committee to be relevant for the study treatment.
Dose-expansion: Number of Participants With Best Overall Response (BOR) as Assessed by Independent Endpoint Review Committee (IRC) From date of randomization up to Week 66 BOR according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and as adjudicated by the Independent Endpoint Review Committee (IRC). BOR is defined as sum of complete response and partial response (CR+PR). For target lesions (TLs), CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the sum of largest diameter (SLD) of the TLs, taking as a reference the baseline SLD.
Dose-expansion: Disease Control Rate According to Response Assessment in Neuro-Oncology (RANO) as Adjudicated by the IRC for Participants With Glioblastoma From date of randomization up to Week 66 DCR is defined as the percentage of participants with a confirmed CR+PR+SD+ Non-CR/non-PD at any time as per RANO criteria. A responder is a participant with a Complete Response (CR) or Partial Response (PR), and a non-responder is a participant with Stable Disease (SD) or Progressive Disease (PD) assessed by the RANO criteria. CR is no T1 gadolinium enhancing disease, no new lesions, or corticosteroids, and stable or decreasing T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR). PR is ≥50% decrease in T1 gadolinium enhancing disease, no new lesions, stable or decreasing T2/FLAIR or corticosteroids, and stable or increasing clinical status. SD is \<50% decrease in T1 gadolinium enhancing disease but \< 25% increase, no new lesions, stable or decreasing T2/FLAIR or corticosteroids, and stable or increase in clinical status. PD is ≥25% increase in T1 gadolinium enhancing disease.
- Secondary Outcome Measures
Name Time Method Trough Plasma Concentration (Ctrough) of M7824 0 hours (Pre-dose), 1, 4, 10, 25, 72, 168, 240, 336 hours post-dose Ctrough is the plasma concentration of a drug prior to administration.
Maximum Concentration (Cmax) of M7824 in Plasma 0 hours (pre-dose), 1, 4, 10, 25, 72, 168, 240, 336 hours post-dose Cmax was obtained directly from the concentration versus time curve.
Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUCtau) of M7824 0 hours (pre-dose), 1, 4, 10, 25, 72, 168, 240, 336 hours post-dose post-dose Area under the concentration-time curve from time zero up to time Tau, where Tau is the dosing interval (336 hours).
Apparent Terminal Half Life (t1/2) of M7824 Pre-dose, 0, 1, 4, 10, 25, 72, 168, 240, 336 hours post-dose Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life is calculated by dividing the natural logarithm to the base e (Log e) multiplied by (\*) 2/ λz, where 'λz' is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Apparent Plasma Clearance (CL) of M7824 0 hours (Pre-dose), 1, 4, 10, 25, 72, 168, 240, 336 hours post-dose CL is defined as the time it takes for the study drug to be completely removed from the body's plasma.
Number of Participants With Best Overall Response (BOR) as Assessed by Investigator From date of randomization up to Week 66 BOR according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and as adjudicated by the Investigator. BOR is defined as sum of complete response and partial response (CR+PR). For target lesions (TLs), CR was defined as the disappearance of all TLs; PR was defined as at least a 30% decrease in the sum of largest diameter (SLD) of the TLs, taking as a reference the baseline SLD.
Dose Expansion: Number of Participants With TEAEs and Serious TEAEs From start of study drug administration up to 200 weeks An Adverse Event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. TEAEs were defined as events with onset date or worsening during the on-treatment period. Serious Adverse Event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Any TEAE included participants with both serious and non-serious AEs.
Dose Expansion: Number of Participants With Treatment-Related TEAEs, Treatment-Related Serious TEAEs and Treatment-related TEAE Leading to Death From start of study drug administration up to 200 weeks Treatment-related TEAEs are any untoward medical occurrence in a participant who received study drug with causal relationship with the investigational product as assessed by the investigator. Related TEAEs were events with relationship missing, unknown or yes. Number of participants with treatment-related TEAEs, treatment-related serious TEAEs and treatment-related TEAE leading to death were reported.
Number of Participants With Positive Anti-Drug Antibody (ADA) of M7824 Predose, up to Week 52 The detection of antibodies to M7824 was performed using a validated immunoassay method with tiered testing of screening, confirmatory and titration. Number of participants with positive ADA of M7824 were reported.
Dose Expansion: Number of Participants With TEAEs and Related TEAEs Based on Severity According to NCI-CTCAE Version 4.03 From start of study drug administration up to 200 weeks AEs were graded according to severity using NCI-CTCAE Version 4.03. Severity of TEAEs were graded as Grade 1: mild (not causing any significant problem, dose adjustment not required), Grade 2: moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event), Grade 3: Severe (caused problem that interferes significantly with usual activities or the clinical status, study drug stopped due to adverse event), Grade 4: Life-threatening, Grade 5: Death. Number of Participants with TEAEs and Related TEAEs Based on Severity having Grade \>= 3 and Grade \>=4 TEAEs were reported.
Trial Locations
- Locations (118)
Pacific Oncology Associates
🇺🇸Escondido, California, United States
Innovative Clinical Research Institute
🇺🇸Whittier, California, United States
Hematology - Oncology Associates of Treasure Coast
🇺🇸Port Saint Lucie, Florida, United States
University Cancer & Blood Center, LLC
🇺🇸Athens, Georgia, United States
Southeastern Regional Medical Center
🇺🇸Newnan, Georgia, United States
Washington University
🇺🇸Saint Louis, Missouri, United States
Michigan State University
🇺🇸Lansing, Michigan, United States
Case Comprehensive Cancer Center
🇺🇸Cleveland, Ohio, United States
Penn State University Milton S. Hershey Medical Center
🇺🇸Hershey, Pennsylvania, United States
Mary Crowley Cancer Research Centers
🇺🇸Dallas, Texas, United States
Texas Oncology, P.A. - Fort Worth
🇺🇸Fort Worth, Texas, United States
Texas Oncology, P.A. - Tyler
🇺🇸Tyler, Texas, United States
Virginia Cancer Specialists, PC
🇺🇸Fairfax, Virginia, United States
Blacktown Hospital
🇦🇺Blacktown, New South Wales, Australia
Virginia Oncology Associates - Hampton
🇺🇸Norfolk, Virginia, United States
Compass Oncology
🇺🇸Vancouver, Washington, United States
St George Hospital
🇦🇺Kogarah, New South Wales, Australia
Liverpool Hospital
🇦🇺Liverpool, New South Wales, Australia
Royal North Shore Hospital
🇦🇺St Leonards, New South Wales, Australia
Gallipoli Medical Research Foundation Ltd
🇦🇺Greenslopes, Queensland, Australia
Calvary Mater Newcastle
🇦🇺Waratah, New South Wales, Australia
Port Macquarie Base Hospital
🇦🇺Port Macquarie, New South Wales, Australia
Tasman Oncology Research Ltd
🇦🇺Southport, Queensland, Australia
The Queen Elizabeth Hospital
🇦🇺Woodville South, South Australia, Australia
Border Medical Oncology Research Unit
🇦🇺Wodonga, Victoria, Australia
Institut Jules Bordet
🇧🇪Bruxelles, Belgium
UZ Antwerpen
🇧🇪Edegem, Belgium
Centre Antoine Lacassagne
🇫🇷Nice cedex 02, Alpes Maritimes, France
Institut Claudius Regaud-Oncopole
🇫🇷Toulouse cedex 09, Haute Garonne, France
CHU de Grenoble - Hôpital Nord
🇫🇷Grenoble cedex 9, Isere, France
Centre Oscar Lambret
🇫🇷Lille cedex, Nord, France
ICO - Site René Gauducheau
🇫🇷Saint Herblain, Loire Atlantique, France
Centre Hospitalier de la Croix Rousse
🇫🇷Lyon Cedex 04, Rhone, France
Centre Léon Bérard
🇫🇷Lyon, Rhone, France
Hôpital Henri Mondor
🇫🇷Créteil Cedex, Val De Marne, France
Institut Régional du Cancer de Montpellier
🇫🇷Montpellier, France
Medizinische Hochschule Hannover
🇩🇪Hannover, Niedersachsen, Germany
Charite Universitaetsmedizin Berlin - Campus Charite Mitte
🇩🇪Berlin, Germany
Universitaetsklinikum Carl Gustav Carus TU Dresden
🇩🇪Dresden, Sachsen, Germany
Fondazione del Piemonte per l'Oncologia IRCC Candiolo
🇮🇹Candiolo, Torino, Italy
Ospedale San Raffaele
🇮🇹Milano, Italy
IEO Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
Fondazione IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
Istituto Nazionale Tumori Fondazione G. Pascale
🇮🇹Napoli, Italy
Policlinico Universitario Agostino Gemelli
🇮🇹Roma, Italy
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, Italy
A.O.U. Senese Policlinico Santa Maria alle Scotte
🇮🇹Siena, Italy
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Kindai University Hospital
🇯🇵Osakasayama-shi, Osaka-Fu, Japan
Chungbuk National University Hospital
🇰🇷Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Clinic i Provincial de Barcelona
🇪🇸Barcelona, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Hospital Infanta Cristina
🇪🇸Badajoz, Spain
Hospital Universitario Ramon y Cajal
🇪🇸Madrid, Spain
Centro Integral Oncologico Clara Campal
🇪🇸Madrid, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario Clinico San Carlos
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Hospital Universitari i Politecnic La Fe
🇪🇸Valencia, Spain
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Southampton General Hospital
🇬🇧Southampton, Hampshire, United Kingdom
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, Strathclyde, United Kingdom
Northern Centre for Cancer Care
🇬🇧Newcastle upon Tyne, Tyne & Wear, United Kingdom
Queen Elizabeth Hospital
🇬🇧Birmingham, West Midlands, United Kingdom
Grand Hôpital de Charleroi
🇧🇪Charleroi, Belgium
Universitair Ziekenhuis Gent
🇧🇪Gent, Belgium
GZA Ziekenhuizen - Campus Sint-Augustinus
🇧🇪Wilrijk, Belgium
Sylvester Cancer Center
🇺🇸Miami, Florida, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Las Vegas, Nevada, United States
UC Health Clinical Trials Office
🇺🇸Cincinnati, Ohio, United States
Oncology Consultants, P.A.
🇺🇸Houston, Texas, United States
University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
🇺🇸Houston, Texas, United States
South Texas Accelerated Research Therapeutics, LLC
🇺🇸San Antonio, Texas, United States
Hôpital de la Timone#
🇫🇷Marseille cedex 5, Bouches-du-Rhône, France
Fiona Stanley Hospital
🇦🇺Murdoch, Western Australia, Australia
Centre Georges François Leclerc
🇫🇷Dijon cedex, Côte-d'Or, France
Linear Clinical Research Limited
🇦🇺Nedlands, Western Australia, Australia
Centre Hospitalier de l'Ardenne
🇧🇪Libramont, Belgium
C. H. U. Sart Tilman
🇧🇪Liège, Belgium
Hôpital Saint-Louis
🇫🇷Paris Cedex 10, Paris, France
Tennessee Cancer Specialists
🇺🇸Knoxville, Tennessee, United States
Cliniques Universitaires Saint-Luc
🇧🇪Bruxelles, Belgium
National Cancer Center Hospital East
🇯🇵Kashiwa-shi, Chiba-Ken, Japan
Greenville Hospital System University Medical Center (ITOR)
🇺🇸Greenville, South Carolina, United States
Metairie Oncologists, LLC
🇺🇸Metairie, Louisiana, United States
Peter MacCallum Cancer Centre-East Melbourne
🇦🇺East Melbourne, Victoria, Australia
Mackay Memorial Hospital
🇨🇳Taipei, Taiwan
Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris
🇫🇷Paris Cedex 05, Paris, France
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Arizona Clinical Research Center
🇺🇸Tucson, Arizona, United States
Eastern Connecticut Hematology/Oncology Assoc.
🇺🇸Norwich, Connecticut, United States
Cabrini Hospital Malvern
🇦🇺Malvern, Victoria, Australia
CHU Bordeaux - Hôpital Saint André
🇫🇷Bordeaux cedex, Gironde, France
California Pacific Medical Center
🇺🇸San Francisco, California, United States
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Groupe Hospitalier Pitie-Salpetriere
🇫🇷Paris cedex 12, Paris, France
Taipei Medical University Hospital
🇨🇳Taipei, Taiwan
University College London Hospitals
🇬🇧London, Greater London, United Kingdom
The Christie
🇬🇧Manchester, Greater Manchester, United Kingdom
Centre Paul Strauss
🇫🇷Strasbourg Cedex, Bas Rhin, France
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Cellex Koeln
🇩🇪Koeln, Nordrhein Westfalen, Germany
University of California Davis Health System
🇺🇸Sacramento, California, United States
Rocky Mountain Cancer Centers, LLP
🇺🇸Denver, Colorado, United States
National Cancer Institute
🇺🇸Bethesda, Maryland, United States
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Texas Oncology, P.A. - Austin
🇺🇸Austin, Texas, United States
Guy's Hospital
🇬🇧London, Greater London, United Kingdom
Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States